Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report

Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland, Laboratory of Clinical Pharmacology, Department of Laboratories, University Hospital of Lausanne, Lausanne, Switzerland, Division of Clinical Pharmacology, Department of Laboratories, University Hospital of Lausanne, Lausanne, Switzerland, Infectious Diseases Service, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland, and Department ‘Femme-MèreEnfant’, University Hospital of Lausanne, Lausanne, Switzerland

[1]  T. Buclin,et al.  Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. , 2016, The Journal of antimicrobial chemotherapy.

[2]  F. Russel,et al.  First reported use of elvitegravir and cobicistat during pregnancy. , 2016, AIDS.

[3]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..

[4]  C. Fletcher,et al.  Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors , 2016, Clinical Pharmacokinetics.

[5]  P. Pennell,et al.  Quantification of neurosteroids during pregnancy using selective ion monitoring mass spectrometry , 2015, Steroids.

[6]  H. Watts,et al.  Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV‐1‐infected pregnant women and relationship to antiretroviral pharmacokinetics , 2015, HIV medicine.

[7]  Weida Tong,et al.  Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  A. Telenti,et al.  A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. , 2013, Journal of mass spectrometry : JMS.

[9]  A. Telenti,et al.  Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction , 2008, Therapeutic drug monitoring.

[10]  J. Fischer,et al.  Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination , 2008, Xenobiotica; the fate of foreign compounds in biological systems.